This clinical guideline supports the safe and consistent use of serum eye drops as an adjunctive treatment for severe ocular surface disease. It explains the role of autologous and allogeneic serum eye drops, sets out when treatment may be appropriate after licensed options have been considered, and outlines recommendations on formulation, frequency, withdrawal strategies and monitoring. It is intended for ophthalmologists, specialist teams and service providers involved in managing complex ocular surface disease.
There is also a lay summary explains serum eye drops in plain English for patients, families and carers. It describes severe ocular surface disease, why serum eye drops may be offered when standard treatments have not worked well enough, and the difference between drops made from a patient’s own blood and donor blood. It also explains why this is a specialised treatment and why careful monitoring and outcome reporting matter.